Abstract Details

Title Recreational drug use and RCVS: should toxicity screens become standard in RCVS diagnostics?

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) (-)

Poster/Presentation
Number 284

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Neha Mirchandani, MD PRESENTER	No disclosure on file
Imad R. Khan, MD (University of Rochester Medical Center)	The institution of Dr. Khan has received research support from National Institute of Neurological Diseases and Stroke. The institution of Dr. Khan has received research support from National Heart Lung and Blood Institute. The institution of Dr. Khan has received research support from National Institute of Neurological Diseases and Stroke.
Fernanda Wajnsztajn, MD (Uconn Health)	An immediate family member of Dr. Wajnsztajn has received personal compensation for serving as an employee of Alexion Pharmaceuticals.
Nicholas S. Abend, MD, FAAN (Children's Hospital of Philadelphia)	Dr. Abend has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Epilepsy Foundation. The institution of Dr. Abend has received research support from NIH. The institution of Dr. Abend has received research support from PCORI. Dr. Abend has received publishing royalties from a publication relating to health care.

��ɫ����